Both alopecia areata (AA) and vitiligo are distinct, heterogenous, and complex disease
entities, characterized by nonscarring scalp terminal hair loss and skin pigment loss …

Alopecia, also known as hair loss, is a highly prevalent condition affecting millions of men
and women in the United States and worldwide, making it one of the most common …

JAK-STAT signalling pathway inhibitors have emerged as promising therapeutic agents for
the treatment of hair loss. Among different JAK isoforms, JAK3 has become an ideal target …

Alopecia areata is an autoimmune disorder that greatly impacts patients' quality of life, and
its management remains challenging. Tofacitinib is the first Janus kinase inhibitor to be …

Background Evidence has demonstrated that Chinese medicine formula Xuefu Zhuyu
decoction can markedly promote the formation of new hair in patients and mice with …

Both alopecia areata (AA) and vitiligo share common pathogenesis involving, interferon‐γ
(IFN‐γ) and interleukin‐15 (IL‐15) signalling pathways that activate cytotoxic CD8+ T …

Severe alopecia areata (AA) is a nonscarring hair loss for immune disorder and SALT
score≥ 50%. The guidelines for managing patients with severe AA suggest treatments …

Alopecia is prevalent among females, categorised as either scarring or non-scarring,
depending on the potential for hair follicle regeneration. Various aetiologic factors are …

Alopecia Areata is a hair disorder influenced by factors such as genetics, immune system,
and environmental triggers. The pathogenesis of this condition is still unclear, leading to …

Background Despite the significant role of JAK3 in various autoimmune diseases, including
graft-versus-host disease (GVHD), there has been a lack of potent and selective JAK3 …